SONOSCAPE(SZ:300633) Sou Hu Cai Jing·2026-01-30 13:20Core Viewpoint - The financial performance of Kaili Medical (300633) shows mixed results, with revenue growth but significant declines in net profit, indicating potential challenges ahead for the company [2]. Group 1: Financial Performance - For the first three quarters of 2025, Kaili Medical reported a main revenue of 1.459 billion yuan, an increase of 4.37% year-on-year [2]. - The net profit attributable to shareholders was 33.51 million yuan, a decrease of 69.25% year-on-year [2]. - The net profit after deducting non-recurring items was 23.99 million yuan, down 72.14% year-on-year [2]. - In Q3 2025, the company achieved a single-quarter main revenue of 495 million yuan, up 28.42% year-on-year [2]. - The single-quarter net profit attributable to shareholders was -13.52 million yuan, an increase of 78.05% year-on-year [2]. - The single-quarter net profit after deducting non-recurring items was -15.89 million yuan, up 76.92% year-on-year [2]. - The company's debt ratio stands at 24.22%, with investment income of 2.08 million yuan and financial expenses of -38.30 million yuan [2]. - The gross profit margin is reported at 60.36% [2]. Group 2: Market Activity - As of January 30, 2026, Kaili Medical's stock closed at 27.75 yuan, reflecting an increase of 0.65% [1]. - The turnover rate was 0.87%, with a trading volume of 37,600 hands and a transaction amount of 104 million yuan [1]. - On January 30, the net inflow of main funds was 2.97 million yuan, accounting for 2.85% of the total transaction amount [1]. - Retail investors experienced a net outflow of 2.17 million yuan, representing 2.08% of the total transaction amount [1]. - Over the past 90 days, 8 institutions have provided ratings for the stock, with 6 buy ratings and 2 hold ratings [2]. - The average target price set by institutions over the past 90 days is 37.0 yuan [2].